RTL therapy for multiple sclerosis: A Phase I clinical study

Halina Offner, Sushmita Sinha, Gregory G. Burrows, Adolph J. Ferro, Arthur A. Vandenbark

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


A human recombinant T cell receptor ligand (RTL1000) consisting of DR2 α1 and β1 domains linked covalently to MOG-35-55 peptide can reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE), and was evaluated for safety in a Phase 1 randomized, placebo-controlled, escalating dose study in 34 subjects with multiple sclerosis (MS). RTL1000 was safe and well tolerated at a dose of ≤ 60. mg that is well within the effective dose range for EAE and did not cause worsening of MS disease at doses ≤ 200. mg. RTL1000 represents a novel approach for the treatment of MS that promises potent immunoregulation and CNS repair without global immunosuppression.

Original languageEnglish (US)
Pages (from-to)7-14
Number of pages8
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - Feb 2011


  • Clinical trial
  • Experimental autoimmune encephalomyelitis (EAE)
  • Multiple sclerosis (MS)
  • Neuroprotection
  • Recombinant T cell receptor ligand (RTL)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'RTL therapy for multiple sclerosis: A Phase I clinical study'. Together they form a unique fingerprint.

Cite this